In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 OmicronBrief Report Published on 2022-02-142022-10-28 Journal: Viruses [Category] COVID-19, COVID19(2023년), SARS, [키워드] affected analysed Analysis antibody antibody epitope bamlanivimab Casirivimab cilgavimab COVID-19 vaccines database epitope Epitopes EUA five groups Mutation mutations neutralisation NTD omicron regdanvimab SARS-CoV-2 sequence Sotrovimab spike mutation submitted the WHO therapeutic three group Tixagevimab Vaccine variant VoC [DOI] 10.3390/v14020390 PMC 바로가기 [Article Type] Brief Report
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialCovid-19 (회복)로 병원에 입원 한 환자의 Casirivimab 및 Imdevimab : 무작위, 통제, 오픈 라벨, 플랫폼 시험Randomized Controlled Trial Published on 2022-02-122022-08-13 Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, 치료제, [키워드] (Medical Research Council 1:1 28-day mortality 95% CI Administered Adverse reaction Adverse reactions All participants all randomly assigned patients all-cause mortality Analysis antibody assigned baseline baseline antibody status bleeding Cardiac arrhythmia Casirivimab cause-specific mortality clinically suspected Combination death detectable died dose Efficacy Efficacy and safety eligible Eligible participants enrolled evaluate finding funding hospital host cells humoral immune response Imdevimab Innovation Intention intention to treat intravenous infusion investigator investigators ISRCTN laboratory-confirmed SARS-CoV-2 infection Local major bleeding events Medical Research Council monoclonal antibody monoclonal antibody combination Mortality mounted non-competing monoclonal antibodies non-competing monoclonal antibody Open-label outcome p value participant Patient Platform trial Primary outcome randomisation randomised randomised, controlled, open-label platform trial Randomly randomly assigned patient rate ratio Receptor binding domain recovery reduced Registered reported Safety SARS-COV-2 infection SARS-CoV-2 spike glycoprotein SARS-CoV-2 vaccine Serious adverse reactions seronegative seronegative patient seronegative patients seropositive seropositive and seronegative patients Seven significantly single intravenous infusion spike glycoprotein Standard of care the SARS-CoV-2 thrombosis Treatment Trial UK hospital usual care usual care alone Viral viral entry with COVID-19 [DOI] 10.1016/S0140-6736(22)00163-5 PMC 바로가기 [Article Type] Randomized Controlled Trial
Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients고형장기 이식 환자의 코로나19 단일클론항체 치료Article Published on 2022-02-012022-09-11 Journal: Transplant infectious disease : an official journa [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] adverse event adverse events age antibody treatment bamlanivimab biopsy Casirivimab casirivimab-imdevimab circulating viral variant circulating viral variants Comparator group confidence confidence interval coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 symptom COVID-19 symptoms deaths Diabetic diagnosed with COVID-19 eligible emergency department Emergency use authorization Follow-up generally mild high risk High-risk patients Hospitalization Imdevimab infusion interval Intervention IQR kidney kidney transplant liver lung median age median time Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 monoclonal monoclonal antibodies monoclonal antibody nine occurred organ Organ transplant outcome Patient patients Ratio receive recipient recipients reduce rejection risk SARS-CoV-2 SARS-CoV-2 spike protein severe coronavirus disease single-center Solid solid organ solid organ transplant SOT Spike protein statistically significant study period the SARS-CoV-2 therapy Transplant treated Treatment two patients Viral Viral variants [DOI] 10.1111/tid.13759 PMC 바로가기 [Article Type] Article
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial초기 무증상 SARS-CoV-2 감염에서 증상이 있는 COVID-19 발병에 대한 피하 카시리비맙 및 임데비맙 항체 조합 대 위약의 효과: 무작위 임상 시험Clinical Trial Published on 2022-02-012022-09-12 Journal: JAMA [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 1:1 age anti-SARS-CoV-2 antibody combination Asymptomatic asymptomatic infection baseline Casirivimab clinical Combination Contact COVID-19 development dose double-blind Effect Efficacy efficacy analysis efficacy end point eligible enrolled evaluate the effect event Follow-up household contact Imdevimab incidence index case individual Odds ratio outcome participant phase 3 trial Placebo placebo-controlled polymerase chain positive Positive test Prevent prevented primary end point progression proportion Randomized receive receiving reduce reduced reduction in reported Result risk Romania RT-qPCR SARS-CoV-2 SARS-COV-2 infection seronegative seronegative participant significantly Subcutaneous symptom duration symptomatic symptomatic disease symptomatic participant symptomatic SARS-CoV-2 infection Treatment treatment-emergent adverse event Viral load women [DOI] 10.1001/jama.2021.24939 PMC 바로가기 [Article Type] Clinical Trial
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days21일 만에 코로나19 단일클론항체 비교효과 적응형 플랫폼 시험 개시Clinical Trial Published on 2022-02-012022-09-12 Journal: Contemporary clinical trials [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Adaptive platform trial antibody bamlanivimab black Casirivimab clinical trial clinical trials clinician COVID-19 Culture decrease demonstrated Effectiveness Efficacy Efficacy and safety etesevimab Hospitalization Imdevimab learning while doing likelihood limit mAb mAbs monoclonal antibodies monoclonal antibody outcome Outpatient Patient progression public health Randomized receiving SARS-CoV-2 severe coronavirus disease Treatment trial infrastructure White patient [DOI] 10.1016/j.cct.2021.106652 PMC 바로가기 [Article Type] Clinical Trial
Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement항 SARS-CoV-2 단일클론항체 요법 투여의 혜택을 받을 수 있는 소아 환자의 적격성 기준: 이탈리아 사회간 합의 선언문Review Published on 2022-01-122022-09-10 Journal: Italian Journal of Pediatrics [Category] 진단, 치료제, [키워드] administration adolescents Adult patients AIFA approved bamlanivimab benefit Casirivimab categories children clinician Comorbidities Comorbidity Consensus COVID19 criteria determinant determinants develop diffusion drug Eligible patients etesevimab Evolution favorable effect FDA food Food and Drug Administration Human Imdevimab increased risk indication indications Infection initial Italian Lilly mAb mAbs Medicine monoclonal antibody pandemic Patient Pediatric patient pediatrics produced progression Regeneron revision risk Risk factors SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pandemic severe COVID-19 severe disease shown Society subject the SARS-CoV-2 therapeutic options therapy [DOI] 10.1186/s13052-021-01187-1 PMC 바로가기 [Article Type] Review
First Case of COVID-19 Treated with Monoclonal Anti-Spike Antibodies in a Patient with Cystic Fibrosis in RomaniaCase Report Published on 2022-01-072022-10-31 Journal: Diagnostics [Category] COVID-19, [키워드] Administered allergies Casirivimab chronic condition close monitoring Comorbidities Complication conditions cough COVID-19 Critical Cystic cystic fibrosis decrease Evolution extrasystole fibrosis foci hemoptysis Imdevimab Inflammatory interstitial pneumonia lung Lung imaging male Moderate COVID-19 monoclonal anti-spike antibodies monoclonal antibody multidrug resistant nasal pancreatic positive RT-PCR progression Pseudomonas aeruginosa repeated required Romania SARS-CoV-2 severe COVID-19 syndrome therapeutic intervention Treatment underlying conditions ventricular [DOI] 10.3390/diagnostics12010137 PMC 바로가기 [Article Type] Case Report
Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factorsShort Report Published on 2022-01-032022-10-30 Journal: Journal of Pharmaceutical Health Care and Sciences [Category] COVID-19, [키워드] 95% CI administration adverse effect Asymptomatic body temperature bradycardia Casirivimab Celsius clinical trial clinical trials computation confidence COVID-19 COVID-19 patient criteria Day died Drug efficacy eligible event events exclusion Factor Fever Follow-up ground glass Ground glass opacity had no hypoxia Imdevimab indicated Inpatient interval Intervention Japan Laboratory Leukocytosis limitation median Multivariate analysis neutralize Neutralizing Other outcome Outpatient oxygen supply Patient pulse oximetry Ratio Retrospective study risk risk factor Risk factors SARS-CoV-2 temperature Two patient vaccination vaccinee was used White blood cell with COVID-19 worsening [DOI] 10.1186/s40780-021-00233-8 PMC 바로가기 [Article Type] Short Report
Monoclonal antibody therapies in the management of SARS-CoV-2 infectionSARS-CoV-2 감염 관리의 단일클론항체 요법Article Published on 2022-01-012022-09-11 Journal: Expert opinion on investigational drugs [Category] SARS, 변종, 진단, [키워드] accelerated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Algorithm antibody approval Area bamlanivimab Bamlanivimab and etesevimab Casirivimab casirivimab and imdevimab clinical evidence combined treatment coronavirus COVID COVID-19 Disease progression domain driving early stage early stages effective epitope etesevimab expert facilitate highlight Hospitalization Imdevimab management monoclonal antibody therapy morbidity Mortality NAb NAbs Neutralizing Neutralizing antibodies offer offered pandemic progresses potential benefit potential benefits potential therapies Prevent provided regdanvimab Regulatory respiratory risk SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus Sotrovimab specificity Spike protein targeted epitope the disease the spike protein therapeutic therapeutic intervention Treatment treatment approach treatment approaches treatments for COVID-19 variants Viral viral replication [DOI] 10.1080/13543784.2022.2030310 PMC 바로가기 [Article Type] Article
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients사설: 입원하지 않은 환자의 SARS-CoV-2 감염에 대한 경구용 항바이러스제 치료 현황Editorial Published on 2022-01-012022-09-11 Journal: Medical science monitor : international medical jo [Category] SARS, 변종, 신약개발, 진단, 치료제, [키워드] administration antiviral drug antiviral drug treatment antiviral drugs approval approved bamlanivimab can be used Casirivimab children Community community setting costly COVID-19 current drug drug treatments early stage early stages editorial effective Emergency use authorization etesevimab EUA FDA healthcare facility Healthcare Products Regulatory Agency Hospitalization Imdevimab increased risk intravenous Intravenous administration Medicine Medicines MHRA Mild Moderate COVID-19 molnupiravir neutralizing monoclonal antibodies Nirmatrelvir oral Paxlovid positive priority product progression Regulatory Remdesivir Ritonavir SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 test SARS-CoV-2 virus severe COVID-19 status the SARS-CoV-2 virus therapeutic Treatment variants of concern [DOI] 10.12659/MSM.935952 PMC 바로가기 [Article Type] Editorial